A mobile cancer screening service.

Nurs Mirror Midwives J

Published: October 1975

Download full-text PDF

Source

Publication Analysis

Top Keywords

mobile cancer
4
cancer screening
4
screening service
4
mobile
1
screening
1
service
1

Similar Publications

Background: Sunburn and intermittent sun exposure elevate melanoma skin cancer risk. Sun protection behaviours, including limiting sun exposure, seeking shade, wearing protective gear, and using sunscreen, help mitigate excessive sun exposure. Smartphone apps present a promising platform to enhance these behaviours.

View Article and Find Full Text PDF

Background: Skin cancers, including melanoma and keratinocyte cancers, are among the most common cancers worldwide, and their incidence is rising in most populations. Earlier detection of skin cancer leads to better outcomes for patients. Artificial intelligence (AI) technologies have been applied to skin cancer diagnosis, but many technologies lack clinical evidence and/or the appropriate regulatory approvals.

View Article and Find Full Text PDF

Background: Social behavioral research studies have increasingly shifted to remote recruitment and enrollment procedures. This shifting landscape necessitates evolving best practices to help mitigate the negative impacts of deceptive attempts (eg, fake profiles and bots) at enrolling in behavioral research.

Objective: This study aimed to develop and implement robust deception detection procedures during the enrollment period of a remotely conducted randomized controlled trial.

View Article and Find Full Text PDF

Objective: Cancer remains a leading cause of morbidity and mortality globally, with India experiencing a significant cancer burden. Effective population-based cancer screening is crucial for early detection and reduction of cancer-related deaths. This study aims to develop a mobile application-based Cancer Screening and Surveillance System (CSMS) to enhance the efficiency and effectiveness of population-based cancer screening by community health workers (CHWs).

View Article and Find Full Text PDF

Background: Selpercatinib, a selective RET kinase inhibitor, is approved for treating various cancers with RET gene mutations such as RET-rearranged thyroid cancer and non-small cell lung cancer. The presence of process-related and degradation impurities in its active pharmaceutical ingredient (API) can significantly affect its safety and effectiveness. However, research on detecting these impurities is limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!